본문바로가기
Language
Q
U
I
C
K

Science & Technology

SK bioscience offers total vaccine solutions thanks to the company’s efficient R&D process
and professional manufacturing process infrastructure.

Pipeline

With the paradigm shift in medical service and the spread of infectious diseases that threaten the human race,
boundless potential lies ahead for the vaccine market.

SK bioscience continues to invest in vaccine research, which will be the engine powering the life science business going forward,
and strives to secure R&D technology and broaden the product portfolio.

Domestic Vaccine Market

(Year of 2017~2028, Unit: billion $)

  • 0
  • 20
  • 40
  • 60
  • 80
  • 100
  • 120

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

Source: BIS Research, Global Vaccine Market - Analysis and Forecast: 2018 to 2028, 2018.11, Recreated by Biotech Policy Research Center(BPRC)

The rapidly aging population, increase in infectious diseases, and the advent of blockbuster vaccines have accelerated the growth of the global vaccine market.

The growing vaccine industry is resulting in improved profitability, new research and manufacturing technology development, and new funding opportunities.

In recent years, the development of therapeutic vaccines that can treat diseases that have already occurred (viruses, cancers, etc.) is also on the rise,
following preventive vaccines that stop infectious diseases in advance.

Vaccines are the most effective, efficient, and convenient means of preventing and treating infectious diseases,
and vaccination is emerging as an important task in public health policy. It is also becoming a global security issue due to the outbreak of transboundary epidemics.
Vaccine Pipeline
Approved iconApproved
PIPELINE - SKYVAX, Phase Ⅰ/ Ⅱ, Phase Ⅲ, BLA, Commercial, WHO PQ
Basic Research / Preclinical Phase I Clinical Trial Phase II Clinical Trial Phase III Clinical Trial Commercialization
chk
chk
chk
chk
COVID-19 Vaccine
CEPIBILL MELINDA GATES FOUNDATION
chkGlobal
Combo Vaccine
(COVID-19 + Flu)
chk
Universal Coronavirus
Vaccine (Sarbecovirus)
CEPIprotein design
chk
Nasal Spray*
IAVIBILL MELINDA GATES FOUNDATION
chk
COVID-19 mRNA Vaccine
chk
Next-Gen
Pneumococcal Vaccine
SANOFL RASTEUR
chkU.S.
RSV Vaccine
chk
Cancer Immunotherapies,
Obesity Vaccines, etc
chk
NRRV¹ Vaccine*
PATHBILL MELINDA GATES FOUNDATION
chkAfrica
Typhoid Conjugate Vaccine
INTERNATIONAL VACCINE INSTITUTEBILL MELINDA GATES FOUNDATION
chkEarned
a biologics license
for export
Cervical Cancer Vaccine
(4-/10-valent)
chk Phase I/II
Clinical Trial
Rotavirus Vaccine
chk
iNTS² Vaccine*
(Non-Typhoidal Salmonella)
chk
Hepatitis A, Recombinant
Herpes Zoster Vaccines, etc.
chk
Etc.
Development and global M&A in progress

1 Non-Replicating Rotavirus Vaccine
2 Invasive Non-Typhoidal Salmonella
* Collaboration Project